Roquefort Therapeutics plc

LSE ROQ.L

Roquefort Therapeutics plc Return on Capital Employed (ROCE) for the year ending December 31, 2023

Roquefort Therapeutics plc Return on Capital Employed (ROCE) is NA for the year ending December 31, 2023. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.
Key data
Date Return on Capital Employed (ROCE) Interest Coverage Ratio Debt to Equity Ratio Return on Common Equity
Market news
SV Wall Street
LSE: ROQ.L

Roquefort Therapeutics plc

CEO Mr. Trevor Ajanthan Reginald
IPO Date March 22, 2021
Location United Kingdom
Headquarters Eccleston Yards
Employees 10
Sector Healthcare
Industries
Biotechnology Clinical Trials Pharmaceuticals Vaccines Venture Capital
Description

Roquefort Therapeutics plc operates as a biotechnology research company. The company engages in the research and development of drugs targeting Midkine, a circulating growth factor protein and pro-inflammatory mediator for the treatment of cancer. Roquefort Therapeutics plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

StockViz Staff

February 7, 2025

Any question? Send us an email